Peter Verwaijen
Vertrieb & Marketing bei EGETIS THERAPEUTICS AB
Profil
Mr. Peter Verwaijen is a Global Head-Marketing & Brand Strategy at Egetis Therapeutics AB.
Mr. Verwaijen was previously employed as a Vice President-Finance by AM-Pharma BV and a Controller by Glaucus Proteomics BV.
Aktive Positionen von Peter Verwaijen
| Unternehmen | Position | Beginn |
|---|---|---|
| EGETIS THERAPEUTICS AB | Vertrieb & Marketing | 05.05.2022 |
Ehemalige bekannte Positionen von Peter Verwaijen
| Unternehmen | Position | Ende |
|---|---|---|
AM-Pharma BV
 AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Finanzdirektor/CFO | - |
Glaucus Proteomics BV
 Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Comptroller/Controller/Auditor | - |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| EGETIS THERAPEUTICS AB | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Glaucus Proteomics BV
Glaucus Proteomics BV Miscellaneous Commercial ServicesCommercial Services Glaucus Proteomics BV develops antibody and protein array technologies to optimize drug development and disease management. The company was founded in 2000 and is headquartered in Utrecht, the Netherlands. | Commercial Services |
AM-Pharma BV
AM-Pharma BV BiotechnologyHealth Technology AM-Pharma BV operates as a biopharmaceutical company. It engages in the development of proprietary recombinant human Alkaline Phosphatase. The firm’s products include Acute Kidney Injury, Inflammatory Bowel Diseases and Hypophosphatasia. The company was founded in 2001 and is headquartered in Bunnik, the Netherlands. | Health Technology |
